Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program – Maryville Daily Times

KENILWORTH, N.J.--(BUSINESS WIRE)--May 7, 2020-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from its oncology program will be presented at the 2020 American Society of Clinical Oncology (ASCO20) Virtual Scientific Program from May 29-31. More than 80 abstracts in nearly 20 types of solid tumors and blood cancers have been accepted across Mercks broad cancer portfolio and investigational pipeline, including KEYTRUDA, Mercks anti-PD-1 therapy; LENVIMA (in collaboration with Eisai); LYNPARZA (in collaboration with AstraZeneca); and MK-6482 (formerly PT2977), an investigational, oral hypoxia-inducible factor-2 alpha (HIF-2) inhibitor

Read more
Scientists finally explained one of the strangest coronavirus symptoms – BGR

One of the qualities of the novel coronavirus that makes it so dangerous is that it doesnt have many specific symptoms that are telltale signs of an infection. Instead, the most common symptoms include signs that present with other viral infections, including the flu. Fever, cough, and shortness of breath might make you think youve been infected, but it can be something else entirely

Read more
CHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma – Yahoo Finance

Company Announcement Copenhagen, Denmark; April 30, 2020 Genmab A/S (GMAB) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending the use of the subcutaneous formulation of daratumumab for the treatment of adult patients with multiple myeloma in frontline and relapsed / refractory settings. The CHMPs Positive Opinion for the subcutaneous formulation of daratumumab applies to all currently approved daratumumab indications in frontline and relapsed / refractory multiple myeloma settings.

Read more
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update – StreetInsider.com

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot. If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com.

Read more